CHAMPIONS ONCOLOGY, INC. - Common Stock, par value $0.001 per share (CSBR)

Historical Holders from Q3 2015 to Q3 2025

Symbol
CSBR on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
13,838,977
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
5,663,057
Holdings value
$36,665,391
% of all portfolios
0%
Number of holders
26
Number of buys
6
Number of sells
15
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CHAMPIONS ONCOLOGY, INC. - Common Stock, par value $0.001 per share (CSBR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TOCQUEVILLE ASSET MANAGEMENT L.P. 4.4% $4,633,843 608,915 Tocqueville Asset Management L.P. 31 Dec 2024
As of 30 Sep 2025 CHAMPIONS ONCOLOGY, INC. - Common Stock, par value $0.001 per share (CSBR) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,663,057 shares of 13,838,977 outstanding shares and own 41% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of CHAMPIONS ONCOLOGY, INC. - Common Stock, par value $0.001 per share (CSBR) own 41% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BATTERY MANAGEMENT CORP. 17% 2,421,673 0% 3% $15,680,333
NEA Management Company, LLC 12% 1,713,720 0% 0.61% $11,096,337
VANGUARD GROUP INC 2.4% 333,258 +1.9% 0% $2,157,845
TOCQUEVILLE ASSET MANAGEMENT L.P. 2.3% 319,674 -20% 0.03% $2,069,889
MORGAN STANLEY 1.4% 189,600 +45% 0% $1,227,660
RENAISSANCE TECHNOLOGIES LLC 1.2% 167,261 -7.6% 0% $1,083,015
BlackRock, Inc. 0.88% 121,910 +0.89% 0% $789,367
GEODE CAPITAL MANAGEMENT, LLC 0.54% 74,409 -1% 0% $481,907
NORTHERN TRUST CORP 0.34% 46,434 -14% 0% $300,661
ACADIAN ASSET MANAGEMENT LLC 0.26% 36,182 0% 0% $232,000
HighTower Advisors, LLC 0.25% 35,158 0% 0% $227,648
Bank of New York Mellon Corp 0.19% 26,749 0% 0% $173,200
STATE STREET CORP 0.19% 26,203 0% 0% $169,664
DIMENSIONAL FUND ADVISORS LP 0.17% 23,702 +5.8% 0% $153,470
BANK OF AMERICA CORP /DE/ 0.16% 21,777 -14% 0% $141,006
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.14% 19,811 -42% 0% $128,276
CITADEL ADVISORS LLC 0.12% 16,326 0% $105,711
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.1% 14,467 -22% 0% $93,674
MILLENNIUM MANAGEMENT LLC 0.09% 12,635 -47% 0% $81,812
Cambridge Investment Research Advisors, Inc. 0.09% 12,252 0% 0% $79,000
Mesirow Financial Investment Management, Inc. 0.09% 12,000 0% 0% $77,701
GSA CAPITAL PARTNERS LLP 0.08% 10,415 0% 0.01% $67,000
ROYAL BANK OF CANADA 0.05% 6,614 -14% 0% $43,000
WHITTIER TRUST CO 0.01% 800 0% $5,040
SBI Securities Co., Ltd. 0% 16 -38% 0% $104

Institutional Holders of CHAMPIONS ONCOLOGY, INC. - Common Stock, par value $0.001 per share (CSBR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 5,663,057 $36,665,391 -$761,415 $6.48 26
2025 Q2 5,772,731 $42,541,525 -$1,253,103 $7.37 29
2025 Q1 5,917,321 $51,360,014 +$1,723,264 $8.68 33
2024 Q4 5,718,824 $49,008,702 -$371,113 $8.57 24
2024 Q3 5,783,612 $28,164,672 +$38,335 $4.87 21
2024 Q2 5,774,158 $29,850,843 +$747,882 $5.17 23
2024 Q1 5,633,547 $27,601,085 +$42,514 $4.90 24
2023 Q4 5,612,282 $31,482,391 -$753,086 $5.62 23
2023 Q3 5,738,643 $35,637,624 -$450,468 $6.21 28
2023 Q2 5,810,614 $37,033,240 -$275,967 $6.38 27
2023 Q1 5,860,555 $23,555,996 -$669,606 $4.02 29
2022 Q4 6,003,532 $27,075,368 -$820,131 $4.51 27
2022 Q3 6,237,577 $46,781,000 -$101,195 $7.50 27
2022 Q2 6,220,826 $49,800,000 +$418,571 $8.00 27
2022 Q1 6,195,380 $50,369,000 -$90,258 $8.13 27
2021 Q4 6,206,609 $51,745,000 -$921,951 $8.35 29
2021 Q3 6,278,256 $64,114,459 -$3,861,348 $10.21 33
2021 Q2 6,655,344 $68,450,153 -$6,271,556 $10.28 36
2021 Q1 7,201,194 $81,382,735 +$856,252 $11.30 44
2020 Q4 7,131,440 $76,929,434 +$1,001,410 $10.79 46
2020 Q3 7,084,905 $65,541,431 +$877,249 $9.25 45
2020 Q2 6,969,631 $66,613,581 +$4,981,325 $9.56 45
2020 Q1 6,466,834 $47,788,000 +$5,396,239 $7.40 28
2019 Q4 5,735,595 $47,777,000 +$635,595 $8.33 28
2019 Q3 5,731,540 $32,382,000 -$1,578,376 $5.65 30
2019 Q2 5,967,794 $46,727,000 -$1,774,036 $7.83 35
2019 Q1 6,135,684 $60,069,000 +$1,291,252 $9.79 37
2018 Q4 6,039,426 $47,166,000 +$436,336 $7.81 45
2018 Q3 5,687,065 $99,351,000 +$24,496,352 $17.47 35
2018 Q2 4,298,835 $27,271,000 +$1,162,771 $6.34 18
2018 Q1 4,281,229 $15,580,000 +$423,759 $3.64 13
2017 Q4 4,163,006 $16,152,000 +$16,848 $3.88 13
2017 Q3 4,176,790 $15,334,000 +$98,739 $3.68 16
2017 Q2 4,172,600 $10,725,000 +$85,867 $2.57 15
2017 Q1 4,138,713 $13,118,000 -$538,128 $3.17 15
2016 Q4 4,321,802 $10,933,000 -$1,579,267 $2.53 10
2016 Q3 5,129,977 $8,615,000 -$407,141 $1.68 17
2016 Q2 5,370,595 $11,545,000 +$491,701 $2.15 12
2016 Q1 5,141,655 $18,718,000 +$7,584 $3.64 9
2015 Q4 5,139,584 $18,348,000 +$861,852 $3.57 12
2015 Q3 4,897,826 $26,188,000 +$26,187,984 $5.35 9